About Sigma non-opioid intracellular receptor 1
Sigma non-opioid intracellular receptor 1 (SIGMAR1) is a protein
from Homo sapiens identified by UniProt accession
Q99720, 223 residues long.
MolForge cross-references it against 0 known binders and
298 disease associations.
Target properties
| Protein name | Sigma non-opioid intracellular receptor 1 |
|---|
| UniProt accession | Q99720 |
|---|
| Gene | SIGMAR1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 223 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (298)
Diseases linked to this target (Open Targets).
- autosomal recessive distal spinal muscular atrophy 2 · score 0.70
- familial amyotrophic lateral sclerosis · score 0.68
- juvenile amyotrophic lateral sclerosis · score 0.64
- Headache · score 0.61
- Cough · score 0.61
- Nasal congestion · score 0.61
- common cold · score 0.61
- Fever · score 0.60
- pain · score 0.60
- Irritability · score 0.59
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q99720-F1 | alphafold | PREDICTED | 93.69 | — |
Amino-acid sequence (223 residues)
MQWAVGRRWA WAALLLAVAA VLTQVVWLWL GTQSFVFQRE EIAQLARQYA GLDHELAFSR LIVELRRLHP GHVLPDEELQ WVFVNAGGWM GAMCLLHASL SEYVLLFGTA LGSRGHSGRY WAEISDTIIS GTFHQWREGT TKSEVFYPGE TVVHGPGEAT AVEWGPNTWM VEYGRGVIPS TLAFALADTV FSTQDFLTLF YTLRSYARGL RLELTTYLFG QDP
Explore Sigma non-opioid intracellular receptor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets